ANAPTYSBIO INC (ANAB)

US0327241065 - Common Stock

14.21  -0.15 (-1.04%)

After market: 14.4 +0.19 (+1.34%)

Fundamental Rating

4

ANAB gets a fundamental rating of 4 out of 10. The analysis compared the fundamentals against 561 industry peers in the Biotechnology industry. While ANAB has a great health rating, there are worries on its profitability. ANAB is valied quite expensively at the moment, while it does show a decent growth rate.



1

1. Profitability

1.1 Basic Checks

In the past year ANAB has reported negative net income.
In the past year ANAB has reported a negative cash flow from operations.
In the past 5 years ANAB always reported negative net income.
In the past 5 years ANAB always reported negative operating cash flow.

1.2 Ratios

With a decent Return On Assets value of -33.57%, ANAB is doing good in the industry, outperforming 63.96% of the companies in the same industry.
With a Return On Equity value of -196.35%, ANAB is not doing good in the industry: 68.83% of the companies in the same industry are doing better.
Industry RankSector Rank
ROA -33.57%
ROE -196.35%
ROIC N/A
ROA(3y)-22.08%
ROA(5y)-18.68%
ROE(3y)-83.68%
ROE(5y)-56.02%
ROIC(3y)N/A
ROIC(5y)N/A

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for ANAB so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A

8

2. Health

2.1 Basic Checks

ANAB does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, ANAB has less shares outstanding
Compared to 5 years ago, ANAB has less shares outstanding
There is no outstanding debt for ANAB. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.

2.2 Solvency

Based on the Altman-Z score of -1.29, we must say that ANAB is in the distress zone and has some risk of bankruptcy.
ANAB has a Altman-Z score (-1.29) which is in line with its industry peers.
ANAB has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -1.29
ROIC/WACCN/A
WACC10.68%

2.3 Liquidity

ANAB has a Current Ratio of 10.23. This indicates that ANAB is financially healthy and has no problem in meeting its short term obligations.
Looking at the Current ratio, with a value of 10.23, ANAB belongs to the top of the industry, outperforming 81.62% of the companies in the same industry.
A Quick Ratio of 10.23 indicates that ANAB has no problem at all paying its short term obligations.
With an excellent Quick ratio value of 10.23, ANAB belongs to the best of the industry, outperforming 81.80% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 10.23
Quick Ratio 10.23

6

3. Growth

3.1 Past

The earnings per share for ANAB have decreased strongly by -12.18% in the last year.
The Revenue has grown by 282.17% in the past year. This is a very strong growth!
Measured over the past years, ANAB shows a very strong growth in Revenue. The Revenue has been growing by 27.97% on average per year.
EPS 1Y (TTM)-12.18%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%19.15%
Revenue 1Y (TTM)282.17%
Revenue growth 3Y-38.84%
Revenue growth 5Y27.97%
Sales Q2Q%804.67%

3.2 Future

The Earnings Per Share is expected to decrease by -5.89% on average over the next years.
The Revenue is expected to grow by 58.60% on average over the next years. This is a very strong growth
EPS Next Y-2.21%
EPS Next 2Y1.79%
EPS Next 3Y2.98%
EPS Next 5Y-5.89%
Revenue Next Year449.21%
Revenue Next 2Y85.25%
Revenue Next 3Y66.13%
Revenue Next 5Y58.6%

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.

0

4. Valuation

4.1 Price/Earnings Ratio

ANAB reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year ANAB is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y1.79%
EPS Next 3Y2.98%

0

5. Dividend

5.1 Amount

No dividends for ANAB!.
Industry RankSector Rank
Dividend Yield N/A

ANAPTYSBIO INC

NASDAQ:ANAB (1/10/2025, 8:01:18 PM)

After market: 14.4 +0.19 (+1.34%)

14.21

-0.15 (-1.04%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-05 2024-11-05/amc
Earnings (Next)N/A N/A
Inst Owners93.61%
Inst Owner Change0%
Ins Owners1.54%
Ins Owner Change0.12%
Market Cap432.41M
Analysts82.35
Price Target36.11 (154.12%)
Short Float %25.25%
Short Ratio10.63
Dividend
Industry RankSector Rank
Dividend Yield N/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-18.69%
Min EPS beat(2)-69.51%
Max EPS beat(2)32.14%
EPS beat(4)2
Avg EPS beat(4)-9.35%
Min EPS beat(4)-69.51%
Max EPS beat(4)32.14%
EPS beat(8)5
Avg EPS beat(8)-5.52%
EPS beat(12)5
Avg EPS beat(12)-23.88%
EPS beat(16)8
Avg EPS beat(16)-8.77%
Revenue beat(2)1
Avg Revenue beat(2)136.23%
Min Revenue beat(2)-55.74%
Max Revenue beat(2)328.2%
Revenue beat(4)3
Avg Revenue beat(4)161.51%
Min Revenue beat(4)-55.74%
Max Revenue beat(4)328.2%
Revenue beat(8)5
Avg Revenue beat(8)77.16%
Revenue beat(12)5
Avg Revenue beat(12)22.89%
Revenue beat(16)8
Avg Revenue beat(16)30.8%
PT rev (1m)-34.88%
PT rev (3m)-32.18%
EPS NQ rev (1m)0%
EPS NQ rev (3m)3.87%
EPS NY rev (1m)-0.54%
EPS NY rev (3m)8.82%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)72.85%
Revenue NY rev (1m)0.36%
Revenue NY rev (3m)74.89%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 7.56
P/FCF N/A
P/OCF N/A
P/B 5.13
P/tB 5.13
EV/EBITDA N/A
EPS(TTM)-6.08
EYN/A
EPS(NY)-5.86
Fwd EYN/A
FCF(TTM)-3.4
FCFYN/A
OCF(TTM)-3.39
OCFYN/A
SpS1.88
BVpS2.77
TBVpS2.77
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -33.57%
ROE -196.35%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-22.08%
ROA(5y)-18.68%
ROE(3y)-83.68%
ROE(5y)-56.02%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0.12
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 59.71%
Cap/Sales 0.65%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 10.23
Quick Ratio 10.23
Altman-Z -1.29
F-Score4
WACC10.68%
ROIC/WACCN/A
Cap/Depr(3y)132.56%
Cap/Depr(5y)131.66%
Cap/Sales(3y)3.46%
Cap/Sales(5y)4.25%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-12.18%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%19.15%
EPS Next Y-2.21%
EPS Next 2Y1.79%
EPS Next 3Y2.98%
EPS Next 5Y-5.89%
Revenue 1Y (TTM)282.17%
Revenue growth 3Y-38.84%
Revenue growth 5Y27.97%
Sales Q2Q%804.67%
Revenue Next Year449.21%
Revenue Next 2Y85.25%
Revenue Next 3Y66.13%
Revenue Next 5Y58.6%
EBIT growth 1Y5.51%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year9.55%
EBIT Next 3Y3.49%
EBIT Next 5YN/A
FCF growth 1Y-16.94%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-16.78%
OCF growth 3YN/A
OCF growth 5YN/A